NCT06549296 - Clinical Study on Targeted CD19CAR-T Therapy for Autoimmune Diseases | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 13, 2024

Primary Completion Date

August 1, 2026

Study Completion Date

August 1, 2027

Conditions

Systemic Lupus ErythematosusSystemic SclerosisANCA Associated VasculitisIdiopathic Inflammatory MyopathiesSjogren's SyndromeAutoimmune Diseases

Interventions

DRUG

RD06-04 CART Cell Injection

CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide.

Trial Locations (1)

RECRUITING

Xuzhou Medical University Affiliated Hospital, Xuzhou

All Listed Sponsors

lead

Nanjing Bioheng Biotech Co., Ltd.

INDUSTRY